Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

PaxVax Secures $22 Million Series B Financing

12/04/2013 | 07:33am EST

Proceeds to Fund Oral Cholera Vaccine Candidate Phase 3 Program

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has completed a Series B financing round totaling $22 million. The financing was led by Ignition Growth and joined by another existing investor, Ignition Ventures as well as new investors including Blue Haven Initiative, a family office impact investor.

PaxVax will use the new capital to continue to fund the recently initiated Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal international program, which is comprised of cholera challenge, safety, and immunogenicity studies. These studies are being conducted in the U.S., Australia, and Canada for use of PXVX0200 as a traveler's vaccine. In recognition of the lack of any available traveler's vaccine in the U.S. against cholera, and the corresponding unmet medical need, PXVX0200 has been granted Fast Track designation by the U.S. Food and Drug Administration.

"We are grateful for the continued financial support and confidence in our lead vaccine candidate as well as in our business model of doing well by doing good," said Ken Kelley, Chief Executive Officer of PaxVax. "Traditional financial investors such as Ignition and new social impact investors such as Blue Haven can both accomplish their financial and social goals by investing in PaxVax and advancing this novel cholera vaccine."

In addition to the new capital, PaxVax also announced that the company had previously converted $35 million of convertible debt received from 2010 to 2012. The company has raised over $68 million in capital since inception.

About PaxVax

PaxVax is a privately held company established in 2007 to develop and commercialize innovative vaccines against infectious diseases. PaxVax has a clinical-stage product portfolio, including a cholera vaccine that recently initiated Phase 3 clinical trials and a pandemic H5N1 influenza vaccine entering Phase 2 clinical trials. The company also has vaccines entering Phase 1 clinical trials in HIV and anthrax under R&D contracts with the National Institutes of Health. The company's proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target any viral or bacterial protein antigen. The company's vaccine candidates are designed to be easier to manufacture, store, distribute, administer, and deliver across the globe than conventional injectable vaccines while enhancing the desired immune response to the vaccine antigens. PaxVax is headquartered in Menlo Park, Calif., with R&D laboratories and a licensed GMP production facility based in San Diego, Calif.

More information about PaxVax is available at www.PaxVax.com.

For PaxVax
Maurissa Messier, 760-539-7417

© Business Wire 2013
Latest news "Companies"
05:58pBrazil battles Chinese red tape to get active vaccine ingredients
05:58pBrazil's Ultrapar leads negotiation for Petrobras' refinery Refap -filing
05:58pLINDAB INTERNATIONAL : comments market intelligence about on-going divestment of business unit
05:58pResults of Bank of Jamaica US Indexed Note 2024A 19 Jan 2021
05:58pCUSHMAN & WAKEFIELD : What's your take….on workplace ecosystems of the future?
05:57pSTEEL PARTNERS L P : Holdings Releases Letter From Executive Chairman Warren Lichtenstein on Passing of Tommy Lasorda
05:56pNATURA & S A : Notice to the Market - Related Parties Transactions
05:56pPERPETUAL : appoints State Street as new custodian and administrator
05:55pEledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference
05:54pSORTIS HOLDINGS : Plays Key Role In Rescuing Portland's Iconic Ace Hotel
Latest news "Companies"